<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="23503">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02069613</url>
  </required_header>
  <id_info>
    <org_study_id>27294/1</org_study_id>
    <secondary_id>W81XWH-13-1-0005</secondary_id>
    <nct_id>NCT02069613</nct_id>
  </id_info>
  <brief_title>Multimodal Approach to Testing the Acute Effects of Mild Traumatic Brain Injury (mTBI)</brief_title>
  <official_title>Multimodal Approach to Testing the Acute Effects of Mild Traumatic Brain Injury (mTBI)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Huntington Medical Research Institutes</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>U.S. Army Medical Research and Materiel Command</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>Huntington Medical Research Institutes</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the study is to determine the relative roles for various testing modalities
      in the diagnosis and prognosis of mild traumatic brain injury.  Subjects will undergo
      functional brain testing (magnetoencephalography, electroencephalography), anatomical brain
      imaging (diffusion tensor imaging, susceptibility-weighted imaging), neuropsychological
      testing (memory, language, processing speed), sleep patterns using actigraphy, and blood
      testing of candidate biomarkers.  Testing will be done at 3 time points post-injury: 1 day,
      14 days, and 30 days post-injury.  Analysis of these tests collectively will be used to
      develop diagnostic tools for acute mTBI.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Anticipated">February 2017</completion_date>
  <primary_completion_date type="Anticipated">August 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Change in objective measures of brain function (MEG/EEG, blood biomarkers)</measure>
    <time_frame>Day 1, day 14, and day 30 post-injury</time_frame>
    <safety_issue>No</safety_issue>
    <description>For MEG/EEG, resting state analyses of brain function will be conducted to include frequency band analyses localizing, for example, delta slow wave activity, and establishing functional connectivity scores at three time points post injury (day 1, day 14, day 30).  For blood biomarkers, serum levels in approximately ten biomarkers will be measured to determine amount in each and if changes occur at three time points post-injury.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in anatomical measures of brain function (DTI, SWI)</measure>
    <time_frame>Day 1, day 14, and day 30 post-injury</time_frame>
    <safety_issue>No</safety_issue>
    <description>Diffusion Tensor-derived measures will be calculated for control and mTBI participants to determine if changes occur at three time points post-injury (day 1, day 14, day 30).</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Mild Traumatic Brain Injury</condition>
  <arm_group>
    <arm_group_label>Mild traumatic brain injury (mTBI)</arm_group_label>
    <description>Patients admitted to Huntington Memorial Hospital (HMH), Pasadena CA, Emergency Department (ED) diagnosed with mTBI by history (alteration of consciousness, post-traumatic amnesia, loss of consciousness) and normal brain computed tomography (CT).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <description>Patients admitted to HMH ED for minor extremity trauma (sprains) and no evidence of mTBI</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood will be retained for future analysis.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Study participants (control, mTBI) will be referred by the Huntington Hospital Emergency
        Department staff.  ED staff will determine the eligibility criteria.  If consent is
        achieved, testing will occur at pre-determined times:  1 day, 14 days, and 30 days
        post-injury.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        1. Civilian (non-military) presenting to HMH ED.

        Exclusion Criteria:

          1. Prior history of diagnosed TBI.

          2. Other significant non-head injury/trauma or open wound.

          3. Other significant medical co-morbidities, such as heart disease or cancer.

          4. Self-reported current use or substances contributing to ED visit (e.g. illicit drugs,
             medications, alcohol abuse).

          5. Currently diagnosed psychological condition (e.g. depression, PTSD).

          6. Medications for psychological or neurological disorder.

          7. Any implanted metal, such as medical device or braces on teeth.

          8. Injury to the back or other injury that will make it difficult for the participant to
             tolerate tests.

          9. Injury to dominant arm that would cause difficulty using computer or responding to
             stimuli during functional imaging.

         10. Pregnancy.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Warren S Merrifield, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Huntington Medical Research Institutes</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Warren S Merrifield, PhD</last_name>
    <phone>626-344-5344</phone>
    <email>merrifield@hmri.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Michael G Harrington, MB</last_name>
    <phone>626-795-4343</phone>
    <email>mghworks@hmri.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>HMRI MEG Laboratory</name>
      <address>
        <city>Pasadena</city>
        <state>California</state>
        <zip>91105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Warren S Merrifield, Ph.D.</last_name>
      <phone>626-344-5344</phone>
      <email>merrifield@hmri.org</email>
    </contact>
    <contact_backup>
      <last_name>Marie Csete, MD, PhD</last_name>
      <phone>626-795-4343</phone>
      <email>csete@hmri.org</email>
    </contact_backup>
    <investigator>
      <last_name>Warren S Merrifield, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Molecular Neurology Program</name>
      <address>
        <city>Pasadena</city>
        <state>California</state>
        <zip>91105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael G Harrington, MB</last_name>
      <phone>626-795-4343</phone>
      <email>mghworks@hmri.org</email>
    </contact>
    <contact_backup>
      <last_name>Marie Csete, MD, PhD</last_name>
      <phone>626-795-4343</phone>
      <email>csete@hmri.org</email>
    </contact_backup>
    <investigator>
      <last_name>Michael G Harrington, MB</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Hoge CW, McGurk D, Thomas JL, Cox AL, Engel CC, Castro CA. Mild traumatic brain injury in U.S. Soldiers returning from Iraq. N Engl J Med. 2008 Jan 31;358(5):453-63. Epub 2008 Jan 30.</citation>
    <PMID>18234750</PMID>
  </reference>
  <reference>
    <citation>Bigler ED. Neuropsychology and clinical neuroscience of persistent post-concussive syndrome. J Int Neuropsychol Soc. 2008 Jan;14(1):1-22. Review.</citation>
    <PMID>18078527</PMID>
  </reference>
  <reference>
    <citation>Lewine JD, Davis JT, Bigler ED, Thoma R, Hill D, Funke M, Sloan JH, Hall S, Orrison WW. Objective documentation of traumatic brain injury subsequent to mild head trauma: multimodal brain imaging with MEG, SPECT, and MRI. J Head Trauma Rehabil. 2007 May-Jun;22(3):141-55.</citation>
    <PMID>17510590</PMID>
  </reference>
  <reference>
    <citation>Huang MX, Theilmann RJ, Robb A, Angeles A, Nichols S, Drake A, D'Andrea J, Levy M, Holland M, Song T, Ge S, Hwang E, Yoo K, Cui L, Baker DG, Trauner D, Coimbra R, Lee RR. Integrated imaging approach with MEG and DTI to detect mild traumatic brain injury in military and civilian patients. J Neurotrauma. 2009 Aug;26(8):1213-26. doi: 10.1089/neu.2008.0672.</citation>
    <PMID>19385722</PMID>
  </reference>
  <reference>
    <citation>Pelinka LE, Kroepfl A, Schmidhammer R, Krenn M, Buchinger W, Redl H, Raabe A. Glial fibrillary acidic protein in serum after traumatic brain injury and multiple trauma. J Trauma. 2004 Nov;57(5):1006-12.</citation>
    <PMID>15580024</PMID>
  </reference>
  <reference>
    <citation>Vos PE, Lamers KJ, Hendriks JC, van Haaren M, Beems T, Zimmerman C, van Geel W, de Reus H, Biert J, Verbeek MM. Glial and neuronal proteins in serum predict outcome after severe traumatic brain injury. Neurology. 2004 Apr 27;62(8):1303-10.</citation>
    <PMID>15111666</PMID>
  </reference>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 22, 2014</lastchanged_date>
  <firstreceived_date>February 18, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Huntington Medical Research Institutes</investigator_affiliation>
    <investigator_full_name>Warren Merrifield, PhD</investigator_full_name>
    <investigator_title>Research Scientist</investigator_title>
  </responsible_party>
  <keyword>Mild traumatic injury to extremity (for controls)</keyword>
  <keyword>mTBI</keyword>
  <keyword>concussion</keyword>
  <keyword>MEG</keyword>
  <keyword>EEG</keyword>
  <keyword>MRI</keyword>
  <keyword>DTI</keyword>
  <keyword>biomarkers</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Brain Injuries</mesh_term>
    <mesh_term>Wounds and Injuries</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
